Investors Overview

Company Profile

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.

Recent/Upcoming Events
Jun 25, 2022 at 6:30 PM BST

Oral Presentation: Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat: Results of a Placebo-Controlled, Double-Blind, First-in-Human (FIH) Clinical Trial

Speaker: Stephen Harrison, M.D., Visiting Professor of Hepatology, Radcliffe Department of Medicine, University of Oxford and Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, TX

btn Events


Investor Contact

Richard Eisenstadt
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail